JP2024546993A5 - - Google Patents

Info

Publication number
JP2024546993A5
JP2024546993A5 JP2024536143A JP2024536143A JP2024546993A5 JP 2024546993 A5 JP2024546993 A5 JP 2024546993A5 JP 2024536143 A JP2024536143 A JP 2024536143A JP 2024536143 A JP2024536143 A JP 2024536143A JP 2024546993 A5 JP2024546993 A5 JP 2024546993A5
Authority
JP
Japan
Prior art keywords
inhibitor
sequence
fubp1
rtel1
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546993A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/086212 external-priority patent/WO2023111210A1/en
Publication of JP2024546993A publication Critical patent/JP2024546993A/ja
Publication of JP2024546993A5 publication Critical patent/JP2024546993A5/ja
Pending legal-status Critical Current

Links

JP2024536143A 2021-12-17 2022-12-15 Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ Pending JP2024546993A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21215511 2021-12-17
EP21215511.3 2021-12-17
PCT/EP2022/086212 WO2023111210A1 (en) 2021-12-17 2022-12-15 Combination of oligonucleotides for modulating rtel1 and fubp1

Publications (2)

Publication Number Publication Date
JP2024546993A JP2024546993A (ja) 2024-12-26
JP2024546993A5 true JP2024546993A5 (enExample) 2025-12-05

Family

ID=80034933

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536143A Pending JP2024546993A (ja) 2021-12-17 2022-12-15 Ｒｔｅｌ１及びｆｕｂｐ１を調節するためのオリゴヌクレオチドの組み合わせ

Country Status (5)

Country Link
US (1) US20240409939A1 (enExample)
EP (1) EP4448106A1 (enExample)
JP (1) JP2024546993A (enExample)
CN (1) CN119095603A (enExample)
WO (1) WO2023111210A1 (enExample)

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2823959B2 (ja) 1991-10-24 1998-11-11 アイシス・ファーマシューティカルス・インコーポレーテッド 改良された取り込みおよびその他の性質を持つ誘導化オリゴヌクレオチド
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP1015469B2 (en) 1997-09-12 2015-11-18 Exiqon A/S Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
ATE356824T1 (de) 1999-05-04 2007-04-15 Santaris Pharma As L-ribo-lna analoge
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
AU2003264441A1 (en) 2002-09-17 2004-04-08 The Circle For The Promotion Of Science And Engineering Method of screening remedy for proliferative disease
EP2284269B1 (en) 2002-11-18 2017-08-09 Roche Innovation Center Copenhagen A/S Antisense design
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
DK2270162T3 (en) 2003-06-12 2019-01-21 Alnylam Pharmaceuticals Inc PRESERVED HBV AND HCV SEQUENCES USED FOR GEN-SILENCING
WO2006082053A1 (en) 2005-02-02 2006-08-10 Heidelberg Pharma Gmbh 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
WO2007094818A2 (en) 2005-08-10 2007-08-23 Merck & Co., Inc. Novel hiv targets
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
DE602007009487D1 (de) 2006-01-27 2010-11-11 Isis Pharmaceutical Inc 6-modifizierte bicyclische nukleinsäureanaloga
WO2007085485A2 (en) 2006-01-27 2007-08-02 Santaris Pharma A/S Lna modified phosphorothiolated oligonucleotides
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
DK2170917T3 (da) 2007-05-30 2012-10-08 Isis Pharmaceuticals Inc N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US8379066B2 (en) 2007-06-27 2013-02-19 Christie Digital Systems Usa, Inc. Method and apparatus for scaling an image to produce a scaled image
AU2008272918B2 (en) 2007-07-05 2012-09-13 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
US8846637B2 (en) 2010-06-08 2014-09-30 Isis Pharmaceuticals, Inc. Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
ES2730393T3 (es) 2010-10-28 2019-11-11 Benitec Biopharma Ltd Tratamiento contra el VHB
RU2013150331A (ru) 2011-04-20 2015-05-27 Рош Гликарт Аг СПОСОБ И УСТРОЙСТВА ДЛЯ рН-ЗАВИСИМОГО ПРОХОЖДЕНИЯ ГЕМАТОЭНЦЕФАЛИЧЕСКОГО БАРЬЕРА
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
US20140303235A1 (en) 2011-08-11 2014-10-09 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
CA2889044A1 (en) 2012-11-15 2014-05-22 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
MX367083B (es) 2013-06-27 2019-08-05 Roche Innovation Ct Copenhagen As Oligomeros antisentido y conjugados con diana en la proteina-convertasa subtilisina/kexina tipo 9(pcsk9).
US10358643B2 (en) 2014-01-30 2019-07-23 Hoffmann-La Roche, Inc. Poly oligomer compound with biocleavable conjugates
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
AU2015329974B2 (en) 2014-10-10 2019-06-20 F. Hoffmann-La Roche Ag GaINAc phosphoramidites, nucleic acid conjugates thereof and their use
CN105777770B (zh) 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
JP6924744B2 (ja) 2015-07-17 2021-08-25 アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
WO2017178656A1 (en) 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
AU2017285350A1 (en) 2016-06-17 2018-12-20 F. Hoffmann-La Roche Ag Nucleic acid molecules for reduction of PAPD5 or PAPD7 mRNA for treating hepatitis B infection
WO2018098328A1 (en) 2016-11-23 2018-05-31 Alnylam Pharmaceuticals, Inc. Modified rna agents with reduced off-target effect
MA52661A (fr) 2018-04-05 2021-02-17 Centre Leon Berard Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
BR112021000538A2 (pt) 2018-07-13 2021-04-06 F. Hoffmann-La Roche Ag Oligonucleotídeos para modular a expressão de rtel1
JP2023506540A (ja) * 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
JP7634542B2 (ja) * 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Ｂ型肝炎ウイルス感染症を処置するためのｓｅｐｔ９阻害剤の使用

Similar Documents

Publication Publication Date Title
US6150339A (en) Anti-viral guanosine-rich oligonucleotides
AU704549B2 (en) Oligonucleotide N3'-P5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties
US5599922A (en) Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5726297A (en) Oligodeoxyribonucleotide N3' P5' phosphoramidates
JP3330595B2 (ja) ウィルス（ｈｉｖ）増殖抑制
US5849900A (en) Inhibition of viruses by antisense oligomers capable of binding to polypurine rich tract of single-stranded RNA or RNA-DNA hybrids
JP2016502858A5 (enExample)
Imanishi et al. BNAs: novel nucleic acid analogs with a bridged sugar moiety
KR20190038606A (ko) B형 간염 바이러스 감염에 대한 RNAi 작용제
KR930701466A (ko) 안티센스 올리고뉴클레오티드에 의한 a형 인플루엔자 바이러스, 안 아아보 스트레인(ann arbor strain)h2n2의 억제
EP1007655A1 (en) Rnase l activators and antisense oligonucleotides effective to treat rsv infections
JP2021505129A5 (enExample)
RU2005133711A (ru) Антисмысловые олигонуклеотиды (odn) к smad7 и их применение в области медицины
WO1994007367A9 (en) Anti-viral oligomers that bind polypurine tracts of single-stranded rna or rna-dna hybrids
RU2020121752A (ru) Средство для лечения синдрома ангельмана на основе антисмысловой нуклеиновой кислоты
JP2021500016A5 (enExample)
BR112020020220A2 (pt) Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b
JP2019533472A5 (enExample)
JP2021511072A5 (enExample)
JP2024544532A5 (enExample)
JP2020521491A5 (enExample)
JP2023514576A5 (enExample)
JP2025509552A5 (enExample)
CN115768439A (zh) 双链siRNA类似物的缀合物
Wang et al. Biophysical and biochemical properties of oligodeoxynucleotides containing 4′-C-and 5′-C-substituted thymidines